Lesch, S.* ; Blumenberg, V.* ; Stoiber, S.* ; Gottschlich, A.* ; Ogonek, J.* ; Cadilha, B.L.* ; Dantes, Z.* ; Rataj, F.* ; Dorman, K.* ; Lutz, J.* ; Karches, C.H.* ; Heise, C.* ; Kurzay, M.* ; Larimer, B.M.* ; Grassmann, S.* ; Rapp, M.* ; Nottebrock, A.* ; Krüger, S.* ; Tokarew, N.* ; Metzger, P.* ; Hoerth, C.* ; Benmebarek, M.R.* ; Dhoqina, D.* ; Grünmeier, R.* ; Seifert, M.* ; Oener, A.* ; Umut, Ö.* ; Joaquina, S.* ; Vimeux, L.* ; Tran, T.* ; Hank, T.* ; Baba, T.* ; Huynh, D.* ; Megens, R.T.A.* ; Janssen, K.P.* ; Jastroch, M. ; Lamp, D. ; Ruehland, S.* ; Di Pilato, M.* ; Pruessmann, J.N.* ; Thomas, M. ; Marr, C. ; Ormanns, S.* ; Reischer, A.* ; Hristov, M.* ; Tartour, E.* ; Donnadieu, E.* ; Rothenfußer, S. ; Duewell, P.* ; König, L.M.* ; Schnurr, M.* ; Subklewe, M.* ; Liss, A.S.* ; Halama, N.* ; Reichert, M.* ; Mempel, T.R.* ; Endres, S. ; Kobold, S.
     
 
    
        
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
    
    
        
    
    
        
        Nat. Bio. Eng. 5, 1246-1260 (2021)
    
    
    
		
		
			
				The efficacy of adoptive cell therapy for solid tumours is hampered by the poor accumulation of the transferred T cells in tumour tissue. Here, we show that forced expression of C-X-C chemokine receptor type 6 (whose ligand is highly expressed by human and murine pancreatic cancer cells and tumour-infiltrating immune cells) in antigen-specific T cells enhanced the recognition and lysis of pancreatic cancer cells and the efficacy of adoptive cell therapy for pancreatic cancer. In mice with subcutaneous pancreatic tumours treated with T cells with either a transgenic T-cell receptor or a murine chimeric antigen receptor targeting the tumour-associated antigen epithelial cell adhesion molecule, and in mice with orthotopic pancreatic tumours or patient-derived xenografts treated with T cells expressing a chimeric antigen receptor targeting mesothelin, the T cells exhibited enhanced intratumoral accumulation, exerted sustained anti-tumoral activity and prolonged animal survival only when co-expressing C-X-C chemokine receptor type 6. Arming tumour-specific T cells with tumour-specific chemokine receptors may represent a promising strategy for the realization of adoptive cell therapy for solid tumours.
			
			
				
			
		 
		
			
				
					
					Impact Factor
					Scopus SNIP
					Web of Science
Times Cited
					Scopus
Cited By
					
					Altmetric
					
				 
				
			 
		 
		
     
    
        Publikationstyp
        Artikel: Journalartikel
    
 
    
        Dokumenttyp
        Wissenschaftlicher Artikel
    
 
    
        Typ der Hochschulschrift
        
    
 
    
        Herausgeber
        
    
    
        Schlagwörter
        Chimeric Antigen Receptor; Cxc Chemokine; Infiltrating Lymphocytes; Immune Cells; Immunotherapy; Cancer; Recruitment; Expression; Localization; Transduction
    
 
    
        Keywords plus
        
    
 
    
    
        Sprache
        englisch
    
 
    
        Veröffentlichungsjahr
        2021
    
 
    
        Prepublished im Jahr 
        
    
 
    
        HGF-Berichtsjahr
        2021
    
 
    
    
        ISSN (print) / ISBN
        2157-846X
    
 
    
        e-ISSN
        2157-846X
    
 
    
        ISBN
        
    
 
    
        Bandtitel
        
    
 
    
        Konferenztitel
        
    
 
	
        Konferzenzdatum
        
    
     
	
        Konferenzort
        
    
 
	
        Konferenzband
        
    
 
     
		
    
        Quellenangaben
        
	    Band: 5,  
	    Heft: 11,  
	    Seiten: 1246-1260 
	    Artikelnummer: ,  
	    Supplement: ,  
	
    
 
  
        
            Reihe
            
        
 
        
            Verlag
            Nature Publishing Group
        
 
        
            Verlagsort
            London ; New York NY ; Tokyo
        
 
	
        
            Tag d. mündl. Prüfung
            0000-00-00
        
 
        
            Betreuer
            
        
 
        
            Gutachter
            
        
 
        
            Prüfer
            
        
 
        
            Topic
            
        
 
	
        
            Hochschule
            
        
 
        
            Hochschulort
            
        
 
        
            Fakultät
            
        
 
    
        
            Veröffentlichungsdatum
            0000-00-00
        
 
         
        
            Anmeldedatum
            0000-00-00
        
 
        
            Anmelder/Inhaber
            
        
 
        
            weitere Inhaber
            
        
 
        
            Anmeldeland
            
        
 
        
            Priorität
            
        
 
    
        Begutachtungsstatus
        Peer reviewed
    
 
     
    
        POF Topic(s)
        30203 - Molecular Targets and Therapies
90000 - German Center for Diabetes Research
30205 - Bioengineering and Digital Health
    
 
    
        Forschungsfeld(er)
        Immune Response and Infection
Helmholtz Diabetes Center
Enabling and Novel Technologies
    
 
    
        PSP-Element(e)
        G-522100-001
G-501900-221
G-503800-001
    
 
    
        Förderungen
        Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2021-07-12